NCT05010005 2026-04-09
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
Clinical Trials
4 trialsNCT03534323 2026-03-23
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT02158091 2026-02-13
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT05044039 2026-02-02
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Washington University School of Medicine
Phase 1 Active not recruiting